This week, I will appear before an FDA advisory committee to make a case that shouldn’t be controversial: patients ought to be able to get their peptide therapies from their licensed physicians or pharmacists, not an anonymous — and often foreign — website. First, a quick primer, because ...
Healthcare policymakers rarely have the luxury of perfect information. They are often asked to make consequential decisions affecting the entire healthcare system while competing interests and sources of information all pull them in different directions. In those moments, the most important ...
In a time of rising transportation costs brought on by the conflict between the United States and Iran, one part of America’s transportation network has kept its rates remarkably stable: the nation’s freight railroads. Even as the railroads confirm their value to the economy, they face an ...
The History Channel’s recounting of World War II, narrated by Tom Hanks, includes the history of Operation Overlord, the massive D-Day invasion of occupied France. This invasion was a magnificent coalition of the United States, Great Britain, Canada, Australia, the French Resistance, and many ...
In 1980 and 1983, Congress fundamentally changed the course of modern medicine. The Bayh-Dole Act passed in 1980 empowered universities, small businesses and nonprofits to own and commercialize medical discoveries made with federally funded research. And in 1983, the Orphan Drug Act created ...
When it comes to bioweapons, we’ve moved beyond anthrax in the mail. No one wants to think about an AI bioweapon or any other type of biothreat. These threats are a real risk that we must confront now before Americans suffer. We have powerful tools available to protect us, but Washington must ...